| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9688711 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(4 years from now) | |
| US8383596 | CIPLA USA | Antibacterial aminoglycoside analogs |
Jun, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9266919 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(4 years from now) | |
| US8822424 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(4 years from now) | |
Zemdri is owned by Cipla Usa.
Zemdri contains Plazomicin Sulfate.
Zemdri has a total of 4 drug patents out of which 0 drug patents have expired.
Zemdri was authorised for market use on 25 June, 2018.
Zemdri is available in solution;intravenous dosage forms.
Zemdri can be used as method of using plazomicin to treat bacterial infections.
Drug patent challenges can be filed against Zemdri from 26 June, 2027.
The generics of Zemdri are possible to be released after 02 June, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 25, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 25, 2028 |
Drugs and Companies using PLAZOMICIN SULFATE ingredient
NCE-1 date: 26 June, 2027
Market Authorisation Date: 25 June, 2018
Treatment: Method of using plazomicin to treat bacterial infections
Dosage: SOLUTION;INTRAVENOUS
ZEMDRI family patents
